CVS Health Corporation $CVS Shares Acquired by QRG Capital Management Inc.

QRG Capital Management Inc. grew its position in CVS Health Corporation (NYSE:CVS) by 21.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 107,944 shares of the pharmacy operator’s stock after buying an additional 19,210 shares during the quarter. QRG Capital Management Inc.’s holdings in CVS Health were worth $8,566,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in CVS. Caitong International Asset Management Co. Ltd lifted its stake in shares of CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 281 shares in the last quarter. Ares Financial Consulting LLC acquired a new stake in CVS Health in the 4th quarter valued at about $29,000. Corundum Trust Company INC acquired a new stake in CVS Health in the 3rd quarter valued at about $29,000. GoalVest Advisory LLC purchased a new position in CVS Health in the 4th quarter worth approximately $32,000. Finally, Financial Consulate Inc. boosted its holdings in shares of CVS Health by 99.6% during the 4th quarter. Financial Consulate Inc. now owns 499 shares of the pharmacy operator’s stock worth $40,000 after purchasing an additional 249 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Caremark will expand adoption of lower?cost biosimilars across its commercial formularies effective July 1, preferring interchangeable biosimilars over certain reference brands — a move that should lower drug spend for clients and improve PBM margins. PR Newswire: CVS Caremark Expands Biosimilar Adoption
• Positive Sentiment: CVS said it will prefer lower?cost interchangeable biosimilars over J&J’s Stelara on its main formularies starting July 1 — a direct cost?management step that can improve margins but may pressure revenues for affected brand drugs. Reuters: CVS to drop J&J’s Stelara
• Positive Sentiment: HSBC raised its price target on CVS to $85 (hold), signaling modest analyst confidence in upside tied to the company’s earnings and cost actions. That provides some near?term support for the stock. MarketScreener: HSBC adjusts price target on CVS
• Positive Sentiment: Media and commentators (including Jim Cramer) are expressing optimism that CVS will report a strong quarter, which can buoy sentiment into earnings. InsiderMonkey: Jim Cramer on CVS quarter
• Neutral Sentiment: Investor previews and analysts flag Q1 results and cost trends/margins as the main near?term focus; outcomes on utilization and PBM pricing will determine stock direction after the print. MSN: CVS Q1 earnings preview
• Neutral Sentiment: Coverage notes investors are watching cost trends and margins closely in the upcoming earnings release; PBM results and medical cost trajectories will be key. Seeking Alpha: CVS earnings in focus
• Neutral Sentiment: Analysts/press point to two hurdles in the quarter (operational/cost execution and broader healthcare demand); Aetna’s strength in Medicare Advantage is a stabilizer but may not fully offset other pressures. Yahoo Finance: Two hurdles to clear
• Neutral Sentiment: CVS Health Ventures made a strategic investment in Fathom to accelerate autonomous coding — a longer?term efficiency play that could reduce administrative costs across the enterprise. Yahoo Finance: Fathom secures investment
• Negative Sentiment: An opinion piece questions the CVS affiliation with Mass General Brigham — while the partnership could expand primary?care access, it raises concerns about costs, care continuity and potential regulatory/competitive scrutiny that could complicate execution and investor sentiment. Boston Globe: CVS affiliation with Mass General Brigham
• Neutral Sentiment: Industry retail shakeups (reports of rivals closing stores) highlight tough store economics in some markets — an indirect signal that pharmacy/retail footprint optimization remains relevant for CVS strategy. TheStreet: Competitor store closures

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on CVS shares. Wolfe Research cut their price target on CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. Robert W. Baird upped their target price on CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Bank of America reduced their price target on CVS Health from $100.00 to $95.00 and set a “buy” rating on the stock in a report on Tuesday, January 27th. Leerink Partners reissued an “outperform” rating and set a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. Finally, Sanford C. Bernstein upgraded shares of CVS Health from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $91.00 to $94.00 in a research report on Thursday, March 12th. Twenty analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $94.61.

CVS Health Price Performance

CVS stock opened at $80.67 on Wednesday. CVS Health Corporation has a 52-week low of $58.35 and a 52-week high of $85.15. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80. The stock has a market cap of $103.39 billion, a price-to-earnings ratio of 58.46, a price-to-earnings-growth ratio of 0.86 and a beta of 0.60. The business has a fifty day moving average of $76.40 and a two-hundred day moving average of $77.96.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating the consensus estimate of $1.00 by $0.09. The business had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The company’s quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, research analysts anticipate that CVS Health Corporation will post 7.14 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is 192.75%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.